Impact on Outcome in Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) Included in Prospective Clinical Trials (CT)

#2773

Introduction: Access to CT offers cancer pts the opportunity to receive new treatments and better monitoring of efficacy and toxicity. The increase of systemic therapy options in advanced NENs has relegated the inclusion of pts in CT to later lines of treatment as suggested in most guidelines.

Aim(s): We aimed to compare the outcome of pts included in CT during the last decade in our academic center.

Materials and methods: 352 pts with diagnosis between 2007 and 2018 were reviewed in this retrospective single-institution study. All patients with at least one line of systemic treatment for advanced NENs were included. Baseline clinic-pathologic features, treatment schemes and survival were collected.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hernando J

Authors: Hernando J, Vukovic P, Garcia-Alvarez A, Díaz N, Cameselle-Garcia S,

Keywords: Clinical Trial, Neuroendocrine Neoplasms, Overall Survival,